September 5 – 8, 2023 | Boston, MA
The hotly anticipated 13th World Clinical Biomarkers & CDx Summit returns as the only industry-led meeting uniting 600+ senior decision makers in the biomarker and CDx field to accelerate clinically validated and affordable co-development of drug-CDx by overcoming commercialization, reimbursement, and regulatory challenges in oncology and beyond to bring personalized medicine to patients faster.
Whether you are working in Oncology, NASH, or Neuroscience, join 600+ Directors, Heads, and VPs of Clinical Biomarkers, Translational Medicine, Precision Medicine & Companion Diagnostics together with drug and diagnostic developers, regulatory experts, payors, and notified bodies for an exclusive opportunity of knowledge sharing and networking to propel your pipelines and make a marked difference for patient outcomes.
Join Beacon’s Biomarker & Assay’s expert, Dasha Kaloujskaia, on conference Day 1 at 4:30 pm, for an overview of the biomarker and assays lung cancer landscape as part of the plenary Track, and uncover exclusive data insights from the Beacon platform. This is not a session to be missed.
Across 2 days, 50+ world-class industry stakeholders will address the most critical challenges in Biomarker Discovery & Translational Development, Clinical Biomarker Development, and CDx Development & Commercialization, to provide you with unparalleled insights